News for Agent

Daily business news: funding, M&A, launches

Mergers & Acquisitions

Linton Lifesciences Acquires EnvisionTEC's 3D-Bioplotter Platform, Technology and Operations

By ·

Key takeaways

  • Linton Lifesciences acquired the 3D-Bioplotter platform, technology and operations from EnvisionTEC GmbH.
  • The 3D-Bioplotter has been on the market for more than two decades and has a global user community.
  • Linton will keep supporting existing 3D-Bioplotter users while investing in a next-generation version of the platform.

Linton Lifesciences acquired the 3D-Bioplotter platform, along with its technology and operations, from EnvisionTEC GmbH. VoxelMatters reported the deal without a disclosed price. Linton is a Boston biofabrication company that develops bioprinted implants, starting with vascular grafts. EnvisionTEC GmbH is the German 3D printer manufacturer that Desktop Metal acquired in 2021.

What Linton Gains From The 3D-Bioplotter

The 3D-Bioplotter has been on the market for more than two decades. Research groups and product developers around the world have used it to advance work in biomaterials, regenerative medicine and other life science applications. The acquisition adds an established technology base, a global user community and deep technical expertise to Linton's biofabrication capabilities.

Linton now lists a German site in Gladbeck, EnvisionTEC GmbH's historic home, alongside its Boston headquarters. Carlos Carvalho serves as Product Lead for the 3D-Bioplotter. Linton will keep supporting the 3D-Bioplotter and its existing users while it invests in the next generation of the platform.

Linton launched in July 2025. Its CEO is Ricky Solorzano, who previously co-founded the bioprinter maker Allevi, acquired by 3D Systems in 2021, and its CTO is Julio Aleman. The company combines advanced chemistry, robotics and 3D bioprinting in a hybrid manufacturing workflow that deposits synthetic polymers and human biomaterials in a single continuous build. Its first product target is a biofabricated vascular graft for hemodialysis access.

In April 2026 Linton introduced Biofabricated New Approach Methodologies (bfNAMs), perfusable tubular tissue models intended to replace static in vitro testing. Linton is part of the NextFab Ventures portfolio and was a semifinalist in Harvard Innovation Labs' 2026 President's Innovation Challenge.

The company called the deal a new chapter for the 3D-Bioplotter and a step in its mission to bridge biofabrication for the benefit of patient care. Linton's goal is to combine advanced biofabrication systems, biomaterials and implantable therapeutics so it can manufacture increasingly complex biomaterial and regenerative medicine products.

The deal also puts Solorzano back in charge of a commercial bioprinting hardware line, five years after Allevi joined 3D Systems. This time the hardware sits inside a company whose main business is implant development. Linton can now use the Bioplotter as both a revenue-generating research tool and a production platform for its own graft and tissue-model programs.

EnvisionTEC's Route To The Sale

The 3D-Bioplotter came from EnvisionTEC, the German 3D printer manufacturer that Desktop Metal acquired in 2021. After Desktop Metal filed for Chapter 11 in July 2025, EnvisionTEC GmbH was one of the foreign subsidiaries sold to an affiliate of Anzu Partners.

Companies in this story

Sources

Machine-readable: Markdown · JSON